ClinicalTrials.gg
Active, not recruitingNCT00978458Updated Oct 5, 2026

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

A Phase 3 interventional study of temozolomide and 3-dimensional conformal radiation therapy in Brain and Central Nervous System Tumors and Neurotoxicity, sponsored by Eastern Cooperative Oncology Group. Active, not recruiting at 168 sites in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Eastern Cooperative Oncology Group · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 100 studies testing temozolomide in Central Nervous System Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Temozolomide · Central Nervous System Neoplasms.

Enrollment
5th of 84
540 · median 43
Started
2009
with 6 others
Phase 3
9 of 100
none open now
Registered
86th of 100
by date

Among the 100 studies testing temozolomide in Central Nervous System Neoplasms, this one is the 5th largest by enrollment of the 84 interventional ones that give a count, is one of 7 that started in 2009, is one of 9 in phase 3, and was the 86th registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 65 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

2 of the 100 studies testing temozolomide in Central Nervous System Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Central Nervous System Neoplasms studies recruiting now, 34 (61%) set no upper age limit and 19 (34%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing temozolomide in Central Nervous System Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma.

PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.

Read the detailed description

OBJECTIVES:

Primary

  • To determine whether the addition of temozolomide to fractionated radiotherapy improves the progression-free survival (PFS) of patients with symptomatic or progressive low-grade gliomas.
  • To determine whether the addition of temozolomide to fractionated radiotherapy improves the median overall survival (OS) of these patients.

Secondary

  • To determine whether combination therapy with temozolomide and radiotherapy improves or maintains cognition and quality of life compared to radiotherapy alone.
  • To compare the toxicities (severe or worse [≥ grade 3]) of radiotherapy with vs without temozolomide in these patients.
  • To assess the impact of the presence or absence of 1p and 19q deletion on PFS and OS.
  • To determine the impact of 1p and 19q status on PFS and OS of patients treated with temozolomide.
  • To create a tumor and tissue bank, including plasma and germ line DNA, within the ECOG Pathology Coordinating Office.

OUTLINE: This is a multicenter study. Patients are stratified according to age (\< 40 years vs ≥ 40 years), 1p and 19q status (both deleted vs either/both intact vs undeterminable), pre-operative maximum tumor diameter (\< 6 cm vs ≥ 6 cm [based on T2 or FLAIR MRI]), Karnofsky performance status (60-70% vs 80-100%), and contrast enhancement on pre-treatment MRI scan (present vs absent). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).
  • Arm II: Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.

Some patients undergo quality-of-life and neurocognitive (e.g., visual scanning speed, divided attention, language, memory, and fine motor skills) assessments at baseline, annually until disease progression, and at the time of disease progression.

Tumor tissue samples are collected at baseline for confirmation of diagnosis and determination of 1p and 19q deletion status. Peripheral blood, serum, and additional tumor tissue samples may be collected for further research studies.

After completion of study treatment, patients are followed up periodically for up to 15 years.

03

Conditions studied

  • Brain and Central Nervous System Tumors
  • Neurotoxicity

Keywords

  • neurotoxicity
  • adult diffuse astrocytoma
  • adult oligodendroglioma
  • recurrent adult brain tumor
  • adult mixed glioma
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed* supratentorial low-grade glioma, including 1 of the following:

    • Grade 2 astrocytoma
    • Grade 2 oligodendroglioma
    • Grade 2 oligoastrocytoma (mixed glioma containing astrocytoma and oligodendroglioma)
  • NOTE: *If the pathology from multiple procedures supports the diagnosis of a brain tumor, the qualifying pathology of grade 2 astrocytoma, oligodendroglioma, or oligoastrocytoma must be the most recent pathological diagnosis; no pathological diagnosis of grade 3 or 4 glioma at any time
  • Paraffin-embedded tumor specimen available for submission for confirmation of pathological review and determination of 1p and 19q deletion status
  • Patients must currently meet ≥ 1 of the following criteria*:

    • Uncontrolled symptoms, defined as any of the following:

      • Headaches associated with mass effect
      • Uncontrolled seizures despite two different antiepileptic drug regimens (i.e., two antiepileptic drugs tested either sequentially or in combination)
      • Focal neurological symptoms
      • Cognitive symptoms or deficits
    • Tumor progression by serial MRIs, defined as any of the following:

      • New or progressive enhancement
      • New or progressive T2 or FLAIR signal abnormality
    • Age ≥ 40 years
  • NOTE: *Patients \< 40 years of age whose only symptom of low-grade glioma is seizures that are well-controlled on antiepileptic drugs AND who have no evidence of radiographic progression are not eligible.
  • Patients who have undergone gross total resection and have no detectable residual disease are eligible
  • No pilocytic astrocytoma, ganglioglioma, pleomorphic xanthoastrocytoma, or dysembryoplastic neuroepithelial tumors

PATIENT CHARACTERISTICS:

  • performance status 60-100%
  • WBC ≥ 3,000/mm\^3
  • ≥ 1,500/mm\^3
  • count ≥ 100,000/mm\^3
  • Hematocrit ≥ 30%
  • ≤ 2 times (ULN)
  • and ALT ≤ 3 times ULN
  • Creatinine ≤ 2.0 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Able to undergo MRI with and without contrast
  • No other within the past 5 years, except for nonmelanoma skin cancer or cervical carcinoma in situ
  • No uncontrolled infection
  • No known positivity
  • No medical disorder that would increase risks associated with radiotherapy and temozolomide
  • No other disorder that would limit to \< 5 years

PRIOR CONCURRENT THERAPY:

  • No prior radiotherapy, cytotoxic chemotherapy, radiosurgery, or therapy directed at the brain tumor

    • Any number of prior surgical procedures for the brain tumor allowed
  • No prior radiotherapy to the head unless the radiotherapy ports entirely excluded the brain
  • At least 2 weeks since any prior brain surgery (e.g., stereotatic , open biopsy, or resection)
  • At least 6 weeks since prior MRI and chest x-ray

    • If resection is performed, an MRI after surgery is required
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
540 participants (actual)

Study arms

  • Active comparator
    Arm I

    Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).

    Radiation: 3-dimensional conformal radiation therapy · Radiation: intensity-modulated radiation therapy

  • Experimental
    Arm II

    Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.

    Drug: temozolomide · Radiation: 3-dimensional conformal radiation therapy · Radiation: intensity-modulated radiation therapy

Interventions

  • Given orally

  • Radiation3-dimensional conformal radiation therapy

    Given once daily 5 days a week for 5½ weeks

  • Radiationintensity-modulated radiation therapy

    Given once daily 5 days a week for 5½ weeks

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

  2. Overall survival (OS)

Secondary outcomes

  1. Quality of life as assessed by the FACT-BR questionnaire at baseline, annually until disease progression, and at the time of disease progression

  2. Neurocognitive functioning as assessed at baseline, annually until disease progression, and at the time of disease progression

  3. Correlation of pre-treatment 1p and 19q levels in tumor tissue samples with PFS and OS

07

Study locations

168 sites
  • UAB Comprehensive Cancer Center
    Birmingham, Alabama 35294, United States
  • Arizona Oncology Services Foundation
    Phoenix, Arizona 85013, United States
  • Rebecca and John Moores UCSD Cancer Center
    La Jolla, California 92093-0658, United States
  • Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
    Orange, California 92868, United States
  • Aurora Presbyterian Hospital
    Aurora, Colorado 80012, United States
  • St. Anthony Central Hospital
    Denver, Colorado 80204, United States
  • Porter Adventist Hospital
    Denver, Colorado 80210, United States
  • Presbyterian - St. Luke's Medical Center
    Denver, Colorado 80218, United States
  • St. Joseph Hospital
    Denver, Colorado 80218, United States
  • CCOP - Colorado Cancer Research Program
    Denver, Colorado 80222, United States
  • Swedish Medical Center
    Englewood, Colorado 80110, United States
  • Sky Ridge Medical Center
    Lone Tree, Colorado 80124, United States
  • Eastern Connecticut Hematology and Oncology Associates
    Norwich, Connecticut 06360, United States
  • CCOP - Christiana Care Health Services
    Newark, Delaware 19713, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • Florida Hospital Cancer Institute at Florida Hospital Orlando
    Orlando, Florida 32803-1273, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Illinois CancerCare - Bloomington
    Bloomington, Illinois 61701, United States
  • St. Joseph Medical Center
    Bloomington, Illinois 61701, United States
  • Graham Hospital
    Canton, Illinois 61520, United States
  • Illinois CancerCare - Canton
    Canton, Illinois 61520, United States
  • Illinois CancerCare - Carthage
    Carthage, Illinois 62321, United States
  • Memorial Hospital
    Carthage, Illinois 62321, United States
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University
    Chicago, Illinois 60611-3013, United States
  • John H. Stroger, Jr. Hospital of Cook County
    Chicago, Illinois 60612-3785, United States
  • University of Illinois Cancer Center
    Chicago, Illinois 60612-7243, United States
  • University of Chicago Cancer Research Center
    Chicago, Illinois 60637-1470, United States
  • Decatur Memorial Hospital Cancer Care Institute
    Decatur, Illinois 62526, United States
  • Eureka Community Hospital
    Eureka, Illinois 61530, United States
  • Illinois CancerCare - Eureka
    Eureka, Illinois 61530, United States
  • Evanston Hospital
    Evanston, Illinois 60201-1781, United States
  • Galesburg Clinic, PC
    Galesburg, Illinois 61401, United States
  • Illinois CancerCare - Havana
    Havana, Illinois 62644, United States
  • Illinois CancerCare - Kewanee Clinic
    Kewanee, Illinois 61443, United States
  • La Grange Memorial Hospital
    La Grange, Illinois 60525, United States
  • Illinois CancerCare - Macomb
    Macomb, Illinois 61455, United States
  • McDonough District Hospital
    Macomb, Illinois 61455, United States
  • Illinois CancerCare - Monmouth
    Monmouth, Illinois 61462, United States
  • OSF Holy Family Medical Center
    Monmouth, Illinois 61462, United States
  • BroMenn Regional Medical Center
    Normal, Illinois 61761, United States
  • Community Cancer Center
    Normal, Illinois 61761, United States
  • Illinois CancerCare - Community Cancer Center
    Normal, Illinois 61761, United States
  • Community Hospital of Ottawa
    Ottawa, Illinois 61350, United States
  • Oncology Hematology Associates of Central Illinois, PC - Ottawa
    Ottawa, Illinois 61350, United States
  • Cancer Treatment Center at Pekin Hospital
    Pekin, Illinois 61554, United States
  • Illinois CancerCare - Pekin
    Pekin, Illinois 61603, United States
  • Proctor Hospital
    Peoria, Illinois 61614, United States
  • OSF St. Francis Medical Center
    Peoria, Illinois 61615-7827, United States
  • CCOP - Illinois Oncology Research Association
    Peoria, Illinois 61615, United States
  • Oncology Hematology Associates of Central Illinois, PC - Peoria
    Peoria, Illinois 61615, United States
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61636, United States
  • Illinois CancerCare - Peru
    Peru, Illinois 61354, United States
  • Illinois Valley Community Hospital
    Peru, Illinois 61354, United States
  • Illinois CancerCare - Princeton
    Princeton, Illinois 61356, United States
  • Illinois CancerCare - Spring Valley
    Spring Valley, Illinois 61362, United States
  • Valley Cancer Center
    Spring Valley, Illinois 61362, United States
  • Elkhart General Hospital
    Elkhart, Indiana 46515, United States
  • Radiation Oncology Associates Southwest
    Fort Wayne, Indiana 46804, United States
  • Parkview Regional Cancer Center at Parkview Health
    Fort Wayne, Indiana 46805, United States
  • Community Regional Cancer Care at Community Hospital East
    Indianapolis, Indiana 46219, United States
  • Community Regional Cancer Care at Community Hospital North
    Indianapolis, Indiana 46256, United States
  • Howard Community Hospital
    Kokomo, Indiana 46904, United States
  • Center for Cancer Therapy at LaPorte Hospital and Health Services
    La Porte, Indiana 46350, United States
  • Michiana Hematology-Oncology, PC - South Bend
    Mishawaka, Indiana 46545-1470, United States
  • CCOP - Northern Indiana CR Consortium
    South Bend, Indiana 46601, United States
  • Memorial Hospital of South Bend
    South Bend, Indiana 46601, United States
  • CCOP - Iowa Oncology Research Association
    Des Moines, Iowa 50309, United States
  • Mercy Cancer Center at Mercy Medical Center - North Iowa
    Mason City, Iowa 50401, United States
  • Siouxland Hematology-Oncology Associates, LLP
    Sioux City, Iowa 51101, United States
  • Cancer Center of Kansas, PA - Wellington
    Wellington, Kansas 67152, United States
  • Cancer Center of Kansas, PA - Wichita
    Wichita, Kansas 67214, United States
  • CCOP - Wichita
    Wichita, Kansas 67214, United States
  • Via Christi Cancer Center at Via Christi Regional Medical Center
    Wichita, Kansas 67214, United States
  • Cancer Center of Kansas, PA - Winfield
    Winfield, Kansas 67156, United States
  • Louisville Oncology at Norton Cancer Institute - Louisville
    Louisville, Kentucky 40202, United States
  • Norton Suburban Hospital
    Louisville, Kentucky 40207, United States
  • Maine Center for Cancer Medicine and Blood Disorders - Scarborough
    Scarborough, Maine 04074, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231-2410, United States
  • Josephine Ford Cancer Center at Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Genesys Hurley Cancer Institute
    Flint, Michigan 48503, United States
  • Hurley Medical Center
    Flint, Michigan 48503, United States
  • West Michigan Cancer Center
    Kalamazoo, Michigan 49007-3731, United States
  • Lakeland Regional Cancer Care Center - St. Joseph
    Saint Joseph, Michigan 49085, United States
  • Lakeside Cancer Specialists, PLLC
    Saint Joseph, Michigan 49085, United States
  • Fairview Ridges Hospital
    Burnsville, Minnesota 55337, United States
  • Mercy and Unity Cancer Center at Mercy Hospital
    Coon Rapids, Minnesota 55433, United States
  • CCOP - Duluth
    Duluth, Minnesota 55805, United States
  • Fairview Southdale Hospital
    Edina, Minnesota 55435, United States
  • Mercy and Unity Cancer Center at Unity Hospital
    Fridley, Minnesota 55432, United States
  • Hutchinson Area Health Care
    Hutchinson, Minnesota 55350, United States
  • HealthEast Cancer Care at St. John's Hospital
    Maplewood, Minnesota 55109, United States
  • Minnesota Oncology - Maplewood
    Maplewood, Minnesota 55109, United States
  • Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • Hennepin County Medical Center - Minneapolis
    Minneapolis, Minnesota 55415, United States
  • Humphrey Cancer Center at North Memorial Outpatient Center
    Robbinsdale, Minnesota 55422-2900, United States
  • Mayo Clinic Cancer Center
    Rochester, Minnesota 55905, United States
  • CCOP - Metro-Minnesota
    Saint Louis Park, Minnesota 55416, United States
  • Park Nicollet Cancer Center
    Saint Louis Park, Minnesota 55416, United States
  • Regions Hospital Cancer Care Center
    Saint Paul, Minnesota 55101, United States
  • United Hospital
    Saint Paul, Minnesota 55102, United States

Showing the first 100 of 168 sites. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2009 (actual). Primary completion is estimated for Dec 2026, 205 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2009
First posted
Sep 17, 2009
StartActual
Nov 17, 2009
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00978458
Responsible party
Sponsor
First posted
Sep 17, 2009
Start date
Nov 17, 2009
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 5, 2026

Study contacts

David Schiff, MD
study chair · University of Virginia
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion